Related Experiment Video
Updated: Jun 29, 2026

Nephrotoxin Microinjection in Zebrafish to Model Acute Kidney Injury
Published on: July 17, 2016
Association of Vancomycin Plus Piperacillin-Tazobactam With Acute Kidney Injury: Differentiating Pseudo-Injury From
Congqin Chen1, Rijing Zhou2, Jie Fang3
1Department of Pharmacy, Xiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Fujian Branch of National Clinical Research Center for Cardiovascular Diseases, Xiamen, China.
Abstract:
The combination of vancomycin and piperacillin-tazobactam (VPT) is widely used for severe infections, but its potential synergistic nephrotoxicity remains debated. This study used the FDA Adverse Event Reporting System (FAERS) database via AERSMine to assess the risk of AKI with VPT and vancomycin plus carbapenems (VC), compared to other vancomycin-based regimens to evaluate the hypothesis of pseudo-nephrotoxicity versus true nephrotoxicity. Disproportionality analysis was performed using the reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN). Model 1 included all vancomycin-associated reports, while Model 2 focused on reports from healthcare professionals. In Model 1, a safety signal was detected for overall AKI (ROR: 1.31, 95% CI: 1.26-1.37; IC025: 0.21) and changes in creatinine (ROR: 1.23, 95% CI: 1.10-1.38; IC025: 0.12) with VPT. In contrast, no significant disproportionality signal was observed for changes in other biomarkers (ROR: 0.89, 95% CI: 0.70-1.14; IC025: -0.38), severe AKI (ROR: 0.82, 95% CI: 0.76-0.89; IC025: -0.31), or renal replacement therapy (RRT) initiation (ROR: 1.08, 95% CI: 0.90-1.29; IC025: -0.09). No safety signal of increased risk of AKI was detected for VC versus other vancomycin-containing regimens across all subgroups. Model 2 confirmed this trend. These findings suggest that creatinine-defined AKI with VPT may represent pseudotoxicity rather than true nephrotoxicity. Further research is needed to clarify the safety profile of VPT.
Insights
The combination of vancomycin and piperacillin-tazobactam (VPT) may cause creatinine changes that mimic kidney injury, suggesting pseudotoxicity rather than true nephrotoxicity. Further research is needed to confirm the safety of VPT in severe infections.
Area of Science:
- Pharmacovigilance
- Nephrology
- Infectious Diseases
Background:
- Vancomycin and piperacillin-tazobactam (VPT) is a common combination for severe infections.
- The potential for synergistic nephrotoxicity between VPT remains a clinical concern.
- Distinguishing true kidney injury from artifactual changes is crucial for patient management.
Purpose of the Study:
- To assess the risk of acute kidney injury (AKI) associated with VPT compared to other vancomycin regimens.
- To investigate whether observed AKI signals with VPT represent true nephrotoxicity or pseudotoxicity.
- To analyze safety signals using disproportionality analysis in a large adverse event database.
Main Methods:
- Utilized the FDA Adverse Event Reporting System (FAERS) database via AERSMine.
- Performed disproportionality analysis using Reporting Odds Ratio (ROR) and Bayesian Confidence Propagation Neural Network (BCPNN).
- Compared VPT and vancomycin plus carbapenems (VC) regimens against other vancomycin-based treatments, analyzing overall AKI, creatinine changes, and severe AKI.
Main Results:
- A safety signal for overall AKI and creatinine changes was detected with VPT in Model 1 (all reports).
- No significant disproportionality signals were found for severe AKI, other biomarkers, or renal replacement therapy initiation with VPT.
- No increased AKI risk signal was observed for vancomycin plus carbapenems (VC) compared to other vancomycin regimens.
Conclusions:
- Creatinine-defined AKI associated with VPT may represent pseudotoxicity, not true nephrotoxicity.
- The findings suggest that VPT's safety profile regarding kidney injury warrants further investigation.
- Clarifying the distinction between true and pseudo-nephrotoxicity is essential for optimizing antibiotic use.
Related Concept Videos
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury VI: Nursing Management

